SK281729B6 - Neuroprotektívne 3-piperidino-4-hydroxychrománové deriváty, ich analógy, stereoizoméry, farmaceuticky prijateľné soli a spôsob ich prípravy - Google Patents

Neuroprotektívne 3-piperidino-4-hydroxychrománové deriváty, ich analógy, stereoizoméry, farmaceuticky prijateľné soli a spôsob ich prípravy Download PDF

Info

Publication number
SK281729B6
SK281729B6 SK250-91A SK25091A SK281729B6 SK 281729 B6 SK281729 B6 SK 281729B6 SK 25091 A SK25091 A SK 25091A SK 281729 B6 SK281729 B6 SK 281729B6
Authority
SK
Slovakia
Prior art keywords
hydrogen atom
formula
group
compound
atom
Prior art date
Application number
SK250-91A
Other languages
English (en)
Slovak (sk)
Inventor
Todd William Butler
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK281729B6 publication Critical patent/SK281729B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK250-91A 1990-02-06 1991-02-01 Neuroprotektívne 3-piperidino-4-hydroxychrománové deriváty, ich analógy, stereoizoméry, farmaceuticky prijateľné soli a spôsob ich prípravy SK281729B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1990/000674 WO1991012005A1 (en) 1990-02-06 1990-02-06 Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs

Publications (1)

Publication Number Publication Date
SK281729B6 true SK281729B6 (sk) 2001-07-10

Family

ID=22220666

Family Applications (1)

Application Number Title Priority Date Filing Date
SK250-91A SK281729B6 (sk) 1990-02-06 1991-02-01 Neuroprotektívne 3-piperidino-4-hydroxychrománové deriváty, ich analógy, stereoizoméry, farmaceuticky prijateľné soli a spôsob ich prípravy

Country Status (29)

Country Link
US (1) US5356905A (ru)
EP (1) EP0441506B1 (ru)
JP (1) JPH0768214B2 (ru)
KR (1) KR930011041B1 (ru)
CN (1) CN1029960C (ru)
AT (1) ATE108787T1 (ru)
AU (1) AU626490B2 (ru)
BR (1) BR9100490A (ru)
CA (1) CA2035653C (ru)
CZ (1) CZ286218B6 (ru)
DE (2) DE69102893T4 (ru)
DK (1) DK0441506T3 (ru)
EG (1) EG19643A (ru)
ES (1) ES2056571T3 (ru)
FI (1) FI94957C (ru)
HU (1) HU222726B1 (ru)
IE (1) IE63836B1 (ru)
IL (1) IL97100A (ru)
MX (1) MX24433A (ru)
MY (1) MY105293A (ru)
NO (1) NO178399C (ru)
NZ (1) NZ237025A (ru)
PH (1) PH31061A (ru)
PL (1) PL164866B1 (ru)
PT (1) PT96664B (ru)
RU (1) RU2099339C1 (ru)
SK (1) SK281729B6 (ru)
WO (1) WO1991012005A1 (ru)
ZA (1) ZA91830B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018502A1 (en) * 1991-04-18 1992-10-29 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
EP0741724B1 (en) * 1994-01-31 1999-08-11 Pfizer Inc. Neuroprotective chroman compounds
NZ284852A (en) * 1994-08-18 1998-06-26 Pfizer 3-(piperidin-1-yl)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidin-1-yl) alkanol derivatives; medicaments; used as a neuroprotective agent
EP0828513B1 (en) 1995-05-26 2004-01-21 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク エンド カムパニー インコーポレーテッド N−置換非アリール複素環アミジル系nmda/nr2b拮抗薬
WO2005034878A2 (en) * 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (ru) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
DE2507782A1 (de) * 1975-02-22 1976-09-02 Merck Patent Gmbh Tetralon- und indanon-derivate sowie verfahren zu ihrer herstellung
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds

Also Published As

Publication number Publication date
NZ237025A (en) 1992-11-25
IL97100A (en) 1996-06-18
JPH04211058A (ja) 1992-08-03
DE69102893D1 (de) 1994-08-25
CZ286218B6 (cs) 2000-02-16
CA2035653A1 (en) 1991-08-07
IE63836B1 (en) 1995-06-14
ZA91830B (en) 1992-09-30
MY105293A (en) 1994-09-30
RU2099339C1 (ru) 1997-12-20
FI923527A (fi) 1992-08-05
IE910372A1 (en) 1991-08-14
DE69102893T2 (de) 1994-11-03
NO178399B (no) 1995-12-11
EP0441506B1 (en) 1994-07-20
MX24433A (es) 1993-05-01
NO923081L (no) 1992-08-05
EP0441506A3 (en) 1991-11-21
ES2056571T3 (es) 1994-10-01
KR930011041B1 (ko) 1993-11-20
WO1991012005A1 (en) 1991-08-22
FI94957B (fi) 1995-08-15
JPH0768214B2 (ja) 1995-07-26
PL288949A1 (en) 1991-07-29
BR9100490A (pt) 1991-10-29
AU7029391A (en) 1991-09-05
CS25091A3 (en) 1991-09-15
CA2035653C (en) 1999-12-21
IL97100A0 (en) 1992-03-29
NO178399C (no) 1996-03-20
DK0441506T3 (da) 1994-09-05
FI94957C (fi) 1995-11-27
CN1053923A (zh) 1991-08-21
EP0441506A2 (en) 1991-08-14
ATE108787T1 (de) 1994-08-15
PT96664B (pt) 1998-07-31
HU222726B1 (hu) 2003-09-29
EG19643A (en) 1995-09-30
KR910015568A (ko) 1991-09-30
PH31061A (en) 1998-02-05
US5356905A (en) 1994-10-18
DE9101346U1 (ru) 1991-06-06
PT96664A (pt) 1991-10-31
PL164866B1 (pl) 1994-10-31
NO923081D0 (no) 1992-08-05
CN1029960C (zh) 1995-10-11
AU626490B2 (en) 1992-07-30
DE69102893T4 (de) 1995-08-10
FI923527A0 (fi) 1992-08-05

Similar Documents

Publication Publication Date Title
SK281729B6 (sk) Neuroprotektívne 3-piperidino-4-hydroxychrománové deriváty, ich analógy, stereoizoméry, farmaceuticky prijateľné soli a spôsob ich prípravy
EP0554247B1 (en) Neuroprotective indolone and related derivatives
US5436255A (en) Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US6046213A (en) Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
EP0398578B1 (en) 2-piperidino-1-alkanol derivatives as antiischemic agents
KR20000064387A (ko) 1-벤질-4-((5,6-디메톡시-1-인다논)-2-일)메틸피페리딘을제조하기위한방법및중간체
JPH11315063A (ja) 光学活性な2―アミノ―1,2,3,4―テトラヒドロナフタレンおよび3―アミノクロマンの製法
EP0666854B1 (en) Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds
JP3687899B2 (ja) アミノアルキルフェノール誘導体および関連化合物
EP0745591B1 (en) Indanylpiperidines as melatonergic agents
HU205077B (en) Process for produicng hydroquinone derivatives and pharmaceutical compositions comprising such compounds